By Elie Dolgin

In the US, many of the nearly one in ten people suffering from depression rely on so-called ‘third generation’ antidepressants, which typically alter the reuptake of the signaling molecule serotonin. It’s no secret, though, that these drugs can take weeks to kick in, and sometimes carry serious side effects.

However, in the past few months alone, researchers have discovered a suite of potential drug targets for depression. Unlike the previous targets, such as serotonin, dopamine and norepinephrine, which act at the synapse between neurons, the newer targets act within the brain cells.

(Click here to continue reading)

Image by istockphoto